Literature DB >> 27630237

Monitoring Integration over Time Supports a Role for Cytotoxic T Lymphocytes and Ongoing Replication as Determinants of Reservoir Size.

Marilia Rita Pinzone1,2, Erin Graf2, Lindsay Lynch2, Brigit McLaughlin2, Frederick M Hecht3, Mark Connors4, Stephen A Migueles4, Wei-Ting Hwang5, Giuseppe Nunnari6, Una O'Doherty7.   

Abstract

The dynamics of HIV reservoir accumulation off antiretroviral therapy (ART) is underexplored. Levels of integrated HIV DNA in peripheral blood mononuclear cells (PBMCs) were longitudinally monitored before and after antiviral therapy. HIV integration increased over time in both elite controllers (ECs; n = 8) and noncontrollers (NCs; n = 6) before ART, whereas integration remained stable in patients on ART (n = 4). The median annual fold change was higher in NCs than in ECs and negatively correlated with CD4/CD8 T-cell ratio. Cytotoxic T lymphocyte (CTL) function as assessed by infected CD4 T-cell elimination (ICE) and granzyme B activity did not significantly change over time in ECs, suggesting that the gradual increase in integrated HIV DNA observed in ECs was not a result of progressive loss of immune-mediated control. Also, acutely infected (n = 7) but not chronically infected (n = 6) patients exhibited a significant drop in integrated HIV DNA 12 months after ART initiation. In conclusion, in the absence of ART, integrated HIV accumulates over time both in NCs and in ECs, at variable individual rates. Starting ART early in infection leads to a greater drop in integrated HIV DNA than does initiating treatment after years of infection. The increase in integrated HIV DNA over time suggests that early treatment may be of benefit in limiting HIV reservoirs. IMPORTANCE: The establishment of a latent reservoir represents a barrier to cure among HIV-infected individuals. The dynamics of HIV reservoir accumulation over time in patients before antiviral therapy is underexplored, in large part because it is difficult to accurately and reproducibly measure the size of HIV reservoir in this setting. In our study, we compared the dynamics of integrated HIV DNA over time in ECs and NCs before and after ART was initiated. We found that integrated HIV DNA levels progressively increase over time in the absence of ART, but with a higher, albeit variable, rate in NCs compared to ECs. In addition, integrated HIV DNA declines more dramatically when ART is initiated in acute rather than chronic HIV infection, suggesting important differences between acute and chronic infection. Our study highlights the role of HIV replication and CTL control in reservoir accumulation in sanctuary sites and why ART appears to be more effective in acute infection.
Copyright © 2016, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27630237      PMCID: PMC5110192          DOI: 10.1128/JVI.00242-16

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  54 in total

1.  Control of HIV-1 in elite suppressors despite ongoing replication and evolution in plasma virus.

Authors:  Karen A O'Connell; Timothy P Brennan; Justin R Bailey; Stuart C Ray; Robert F Siliciano; Joel N Blankson
Journal:  J Virol       Date:  2010-05-05       Impact factor: 5.103

2.  Persistent low-level viremia in HIV-1 elite controllers and relationship to immunologic parameters.

Authors:  Florencia Pereyra; Sarah Palmer; Toshiyuki Miura; Brian L Block; Ann Wiegand; Alissa C Rothchild; Brett Baker; Rachel Rosenberg; Emily Cutrell; Michael S Seaman; John M Coffin; Bruce D Walker
Journal:  J Infect Dis       Date:  2009-09-15       Impact factor: 5.226

3.  Immune responses driven by protective human leukocyte antigen alleles from long-term nonprogressors are associated with low HIV reservoir in central memory CD4 T cells.

Authors:  Benjamin Descours; Veronique Avettand-Fenoel; Catherine Blanc; Assia Samri; Adeline Mélard; Virginie Supervie; Ioannis Theodorou; Guislaine Carcelain; Christine Rouzioux; Brigitte Autran
Journal:  Clin Infect Dis       Date:  2012-03-22       Impact factor: 9.079

4.  Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy.

Authors:  T W Chun; L Stuyver; S B Mizell; L A Ehler; J A Mican; M Baseler; A L Lloyd; M A Nowak; A S Fauci
Journal:  Proc Natl Acad Sci U S A       Date:  1997-11-25       Impact factor: 11.205

5.  Use of laboratory tests and clinical symptoms for identification of primary HIV infection.

Authors:  Frederick M Hecht; Michael P Busch; Bhupat Rawal; Marcy Webb; Eric Rosenberg; Melinda Swanson; Margaret Chesney; Jennifer Anderson; Jay Levy; James O Kahn
Journal:  AIDS       Date:  2002-05-24       Impact factor: 4.177

6.  Antiretroviral therapy initiated within 6 months of HIV infection is associated with lower T-cell activation and smaller HIV reservoir size.

Authors:  Vivek Jain; Wendy Hartogensis; Peter Bacchetti; Peter W Hunt; Hiroyu Hatano; Elizabeth Sinclair; Lorrie Epling; Tzong-Hae Lee; Michael P Busch; Joseph M McCune; Christopher D Pilcher; Frederick M Hecht; Steven G Deeks
Journal:  J Infect Dis       Date:  2013-07-12       Impact factor: 5.226

7.  Integrated HIV DNA accumulates prior to treatment while episomal HIV DNA records ongoing transmission afterwards.

Authors:  John M Murray; Kristin McBride; Christoph Boesecke; Michelle Bailey; Janaki Amin; Kazuo Suzuki; David Baker; John J Zaunders; Sean Emery; David A Cooper; Kersten K Koelsch; Anthony D Kelleher
Journal:  AIDS       Date:  2012-03-13       Impact factor: 4.177

8.  Long-term antiretroviral therapy initiated during primary HIV-1 infection is key to achieving both low HIV reservoirs and normal T cell counts.

Authors:  Laurent Hocqueloux; Véronique Avettand-Fènoël; Sophie Jacquot; Thierry Prazuck; Eric Legac; Adeline Mélard; Mohamadou Niang; Catherine Mille; Gwenaël Le Moal; Jean-Paul Viard; Christine Rouzioux
Journal:  J Antimicrob Chemother       Date:  2013-01-20       Impact factor: 5.790

9.  HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation.

Authors:  Nicolas Chomont; Mohamed El-Far; Petronela Ancuta; Lydie Trautmann; Francesco A Procopio; Bader Yassine-Diab; Geneviève Boucher; Mohamed-Rachid Boulassel; Georges Ghattas; Jason M Brenchley; Timothy W Schacker; Brenna J Hill; Daniel C Douek; Jean-Pierre Routy; Elias K Haddad; Rafick-Pierre Sékaly
Journal:  Nat Med       Date:  2009-06-21       Impact factor: 53.440

10.  Broad CTL response is required to clear latent HIV-1 due to dominance of escape mutations.

Authors:  Kai Deng; Mihaela Pertea; Anthony Rongvaux; Leyao Wang; Christine M Durand; Gabriel Ghiaur; Jun Lai; Holly L McHugh; Haiping Hao; Hao Zhang; Joseph B Margolick; Cagan Gurer; Andrew J Murphy; David M Valenzuela; George D Yancopoulos; Steven G Deeks; Till Strowig; Priti Kumar; Janet D Siliciano; Steven L Salzberg; Richard A Flavell; Liang Shan; Robert F Siliciano
Journal:  Nature       Date:  2015-01-07       Impact factor: 49.962

View more
  12 in total

1.  Infrequent HIV Infection of Circulating Monocytes during Antiretroviral Therapy.

Authors:  Marta Massanella; Wendy Bakeman; Pasiri Sithinamsuwan; James L K Fletcher; Nitiya Chomchey; Somporn Tipsuk; Thep Chalermchai; Jean-Pierre Routy; Jintanat Ananworanich; Victor G Valcour; Nicolas Chomont
Journal:  J Virol       Date:  2019-12-12       Impact factor: 5.103

2.  Monitoring HIV DNA and cellular activation markers in HIV-infected humanized mice under cART.

Authors:  Mary-Aude Rochat; Erika Schlaepfer; Stefan P Kuster; Duo Li; Annette Audige; Sandra Ivic; Audrey Fahrny; Roberto F Speck
Journal:  Virol J       Date:  2018-12-17       Impact factor: 4.099

3.  Longitudinal HIV sequencing reveals reservoir expression leading to decay which is obscured by clonal expansion.

Authors:  Marilia Rita Pinzone; D Jake VanBelzen; Sam Weissman; Maria Paola Bertuccio; LaMont Cannon; Emmanuele Venanzi-Rullo; Stephen Migueles; R Brad Jones; Talia Mota; Sarah B Joseph; Kevin Groen; Alexander O Pasternak; Wei-Ting Hwang; Brad Sherman; Anastasios Vourekas; Giuseppe Nunnari; Una O'Doherty
Journal:  Nat Commun       Date:  2019-02-13       Impact factor: 14.919

Review 4.  How elite controllers and posttreatment controllers inform our search for an HIV-1 cure.

Authors:  Jonathan Z Li; Joel N Blankson
Journal:  J Clin Invest       Date:  2021-06-01       Impact factor: 19.456

5.  Paradoxically Greater Persistence of HIV RNA-Positive Cells in Lymphoid Tissue When ART Is Initiated in the Earliest Stage of Infection.

Authors:  Eugène Kroon; Suthat Chottanapund; Supranee Buranapraditkun; Carlo Sacdalan; Donn J Colby; Nitiya Chomchey; Peeriya Prueksakaew; Suteeraporn Pinyakorn; Rapee Trichavaroj; Sandhya Vasan; Sopark Manasnayakorn; Cavan Reilly; Erika Helgeson; Jodi Anderson; Caitlin David; Jacob Zulk; Mark de Souza; Sodsai Tovanabutra; Alexandra Schuetz; Merlin L Robb; Daniel C Douek; Nittaya Phanuphak; Ashley Haase; Jintanat Ananworanich; Timothy W Schacker
Journal:  J Infect Dis       Date:  2022-06-15       Impact factor: 7.759

Review 6.  Beyond the replication-competent HIV reservoir: transcription and translation-competent reservoirs.

Authors:  Amy E Baxter; Una O'Doherty; Daniel E Kaufmann
Journal:  Retrovirology       Date:  2018-02-02       Impact factor: 4.602

Review 7.  Measuring integrated HIV DNA ex vivo and in vitro provides insights about how reservoirs are formed and maintained.

Authors:  Marilia Rita Pinzone; Una O'Doherty
Journal:  Retrovirology       Date:  2018-02-17       Impact factor: 4.602

Review 8.  The role of integration and clonal expansion in HIV infection: live long and prosper.

Authors:  Elizabeth M Anderson; Frank Maldarelli
Journal:  Retrovirology       Date:  2018-10-23       Impact factor: 4.602

9.  Persistence of an intact HIV reservoir in phenotypically naive T cells.

Authors:  Emmanuele Venanzi Rullo; Marilia Rita Pinzone; LaMont Cannon; Sam Weissman; Manuela Ceccarelli; Ryan Zurakowski; Giuseppe Nunnari; Una O'Doherty
Journal:  JCI Insight       Date:  2020-10-15

10.  Cells producing residual viremia during antiretroviral treatment appear to contribute to rebound viremia following interruption of treatment.

Authors:  Hadega A Aamer; Jan McClure; Daisy Ko; Janine Maenza; Ann C Collier; Robert W Coombs; James I Mullins; Lisa M Frenkel
Journal:  PLoS Pathog       Date:  2020-08-25       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.